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1. Introduction 
While the last century has seen substantial developments in our understanding of many 
human diseases, there are still vast gaps in our knowledge about many physiological and 
pathological processes. This is particularly so in obstetrics, where advances in care have 
resulted in significant declines in both maternal and perinatal mortality in developed 
countries. Yet, despite this, conditions such as pre-eclampsia, fetal growth restriction, 
stillbirth, miscarriage and placental abruption remain to a large extent idiopathic. Prediction 
and prevention of these complications remains limited, with timely delivery representing 
the only effective treatment strategy in cases of pre-eclampsia, fetal growth restriction and 
placental abruption. This will often result in the delivery of a premature infant who requires 
the investment of significant community and family resources – financial, physical, 
intellectual and emotional – to develop their full potential. The longer term sequelae of fetal 
growth restriction such as adult onset diabetes, hypertension and obesity, (Barker et al. 
1993) and the effects of prematurity such as chronic lung disease (Askie et al. 2005) and 
neurodevelopmental impairment (Guellec et al. 2011) represent significant additional 
burdens. Any improvements that can be made in our understanding and treatment of these 
serious human pregnancy disorders, therefore has the potential to impact significantly not 
only on maternal well being, but also on the well-being of future generations. 
A consistent finding among patients experiencing many of these complications is that of 
areas of thrombosis on histological examination of the placenta (Salafia et al. 1995a; Salafia 
et al. 1995b). This has prompted the suggestion that disturbances in coagulation may 
contribute to the aetiology of these conditions. The recognition of the association between 
inherited thrombophilias and venous thromboembolism has sparked significant interest in 
the possibility that inherited thrombophilias may also play a role in these pregnancy 
complications. In this review, the current state of understanding regarding inherited 
thrombophilia and adverse pregnancy outcome will be critically examined.  
2. Inherited thrombophilias and adverse pregnancy outcomes:  
The limitations of case control studies 
The association between inherited thrombophilias and adverse pregnancy outcomes has 
been intensely debated for the past 15 years. Early case-control studies suggested significant 
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associations between maternal inherited thrombophilias and pregnancy complications such 
as pre-eclampsia (Dekker et al. 1995; van Pampus et al. 1999; Kupferminc et al. 2000), fetal 
growth restriction (Martinelli et al. 2001; Agorastos et al. 2002), placental abruption (Wiener-
Megnagi et al. 1998; Kupferminc et al. 1999), stillbirth (Preston et al. 1996; Many et al. 2002) 
and recurrent miscarriage (Grandone et al. 1997; Younis et al. 2000).   Despite the potential 
for confounding (de Vries et al. 2009) and bias (Sibai 2005) inherent in these early case 
control studies, their great strength is the fact that they examined the association between 
thrombophilias and severe, early onset complications. These complications are rare but 
extremely serious by virtue of the increased likelihood of long term maternal and perinatal 
sequelae. Follow up case control studies often included patients with milder forms of the 
condition, later onset of disease and delivery at more advanced gestations, and as a result, 
often failed to confirm the significant associations between thrombophilias and adverse 
pregnancy outcomes demonstrated in early case control studies. This is best exemplified by 
contrasting two studies investigating the association between fetal growth restriction and 
inherited thrombophilia (Infante-Rivard et al. 2002; Kupferminc et al. 2002). Kupferminc and 
colleagues restricted their analysis to the subgroup of women delivering severe early onset 
growth restricted babies with a birthweight below the 3rd centile and antenatal ultrasound 
evidence of oligohydramnios (Kupferminc et al. 2002) while Infante-Rivard used the more 
liberal definition of birthweight less than the 10th centile (Infante-Rivard et al. 2002). 
Kupferminc and colleagues calculated the highly significant odds ratio of 4.5 (2.3 – 9.0) for 
the association between any inherited thrombophilia and fetal growth restriction (FGR), 
whereas Infante-Rivard concluded that an association between fetal growth restriction and 
inherited thrombophilias did not exist. Such a difference is likely to be due to differences in 
the clinical definitions chosen. On the one hand Kupferminc’s FGR population represents a 
small unique subgroup representing less than 0.2% of their entire obstetric population 
(Kupferminc et al. 2002). Meanwhile Infante-Rivard’s FGR population represents a much 
broader group which is likely to include many women with healthy babies that are merely 
constitutionally small. This is further supported by the low rates of significant placental 
pathology in this group (Infante-Rivard et al. 2002). Most importantly, however, the 
majority of Infante-Rivard’s cohort are likely to have excellent perinatal outcomes with low 
rates of prematurity and associated morbidity, a finding that contrasts starkly with the high 
perinatal mortality (approximately 60%), universal prematurity and associated morbidity 
described in Kupferminc’s study (Kupferminc et al. 2002). While it is true that a statistically 
significant association is seen with the Kupferminc study, it must be emphasised that this is 
a highly specific, high risk population and these findings cannot necessarily be extrapolated 
to general obstetric populations.  
The limitation to the study validity that is imposed by varying clinical definitions is evident 
not just with fetal growth restriction as described above, but also pre-eclampsia, fetal loss 
and placental abruption. Studies investigating the relationship between miscarriage and 
thrombophilias have variably defined recurrent miscarriage as two or more first trimester 
losses (Younis et al. 2000), three or more first trimester losses (Rai et al. 2001) or any number 
of second trimester losses (Raziel et al. 2001). Furthermore, miscarriage and stillbirth have 
not infrequently been combined making dissection of individual associations very difficult 
(Preston et al. 1996). 
The potential for publication bias in case control studies with positive association studies 
being rapidly published while studies that do not confirm these associations have been 
delayed has also been suggested in several meta-analyses that examined the potential 
impact of publication bias (Howley et al. 2005; Facco et al. 2009). In addition, many of the 
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early “positive” studies were published in high impact journals (Dekker et al. 1995; Preston 
et al. 1996; de Vries et al. 1997; Kupferminc et al. 1999; Rey et al. 2003) and were thus rapidly 
disseminated amongst the obstetric and haematology communities. Rapid translation of 
these preliminary research findings into clinical practice has also been a key issue. This has 
happened simply because thrombophilia tests were readily available to clinicians who were 
keen to take advantage of them. Furthermore, the publication of eminent guidelines (Bates 
et al. 2004) and influential articles (Kupferminc et al. 1999) advising of the merits of testing 
women who experience adverse pregnancy events (before the appearance of evidence to 
support treatment or prophylaxis for subsequent pregnancies) has resulted in the very high 
uptake of thrombophilia testing by obstetricians. This has confounded ongoing rigorous 
research examining the efficacy of testing and treatment in this field.  
Another significant limitation of case-control studies is the variation in the ethnic 
distribution of inherited thrombophilias. A number of studies have now highlighted the 
significant ethnic variation in the prevalence of various thrombophilias (Rees et al. 1995; 
Herrmann et al. 1997; Said et al. 2006; Said et al. 2008) but it is important to note that even 
within predominantly Caucasian populations, significant ethnic variation in the prevalence 
of inherited thrombophilias exists by virtue of different migration patterns (Said et al. 2006). 
Failure to take into account the specific prevalence of inherited thrombophilias in the ethnic 
group being studied, and account for the potential interaction of other co-inherited 
thrombophilias, can result in studies that are underpowered and thus unable to answer 
questions regarding the association between inherited thrombophilias and adverse obstetric 
outcomes.  
3. Meta-analysis of case control studies 
A number of meta-analyses examining the association between inherited thrombophilias 
and adverse pregnancy outcomes on the basis of case control studies have been undertaken 
(McLintock et al. 2001; Alfirevic et al. 2002; Rey et al. 2003; Howley et al. 2005; Lin and 
August 2005; Robertson et al. 2006; Facco et al. 2009).  Meta-analyses of case control studies 
are limited by the significant heterogeneity of the included studies but nevertheless attempt 
to provide a clinically relevant evidence base to support decision making regarding testing 
for inherited thrombophilias in these obstetric conditions. As stated previously however, 
meta-analyses have limited validity due to the effects of publication bias and clinical 
heterogeneity.  
As with case control studies, meta-analyses examining the association between inherited 
thrombophilias and pre-eclampsia have invariably concluded that overall, the strength of 
association may be weak at best with the greatest association observed with severe early 
onset disease.  Lin and August included a total of 31 published studies and 7522 patients in 
their meta-analysis and calculated a modest odds ratio of 1.81 (1.14 - 2.87) for the association 
between the factor V Leiden mutation and pre-eclampsia overall and an odds ratio of 2.24 
(1.28 – 3.94) for severe pre-eclampsia (Lin and August 2005). In contrast a statistically 
significant association was not observed with either the prothrombin gene mutation or the 
MTHFR 677 polymorphism. Once again, however, funnel plot analysis for publication bias 
suggested the possibility of publication bias due to the absence of smaller, negative studies 
available for inclusion in the meta-analysis.  
A comprehensive review of published studies investigating genetic risk factors for placental 
abruption revealed a positive association between the prothrombin gene mutation (OR 6.67, 
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3.21 - 13.88, 7 included studies) and the factor V Leiden mutation (OR 2.35, 1.62 – 3.41, 10 
studies) (Zdoukopoulos and Zintzaras 2008). Interestingly the strength of these associations 
increased significantly when studies comprising non-Caucasian women were excluded since 
both these mutations are more frequently present in Caucasian compared to non-Caucasian 
populations.  
Rey and colleagues took up the challenge of dissecting the associations between inherited 
thrombophilias and fetal loss in their meta-analysis published in The Lancet in 2003 (Rey et 
al. 2003). After categorising fetal loss as early recurrent loss and late non-recurrent loss (after 
19 weeks), they concluded first trimester recurrent fetal loss was associated with factor V 
Leiden (OR 2.01, 1.13 - 3.58) and prothrombin gene mutation (OR 2.05, 1.18 - 3.54) while  late 
non-recurrent loss was associated with factor V Leiden (OR 3.26, 1.82 – 5.83), prothrombin 
gene mutation (OR 2.30, 1.09 – 4.87) and protein S deficiency (OR 7.39, 1.28 – 42.83) (Rey et 
al. 2003).  
The relationship between fetal growth restriction and inherited thrombophilias has been the 
subject of several meta-analyses of case control studies (Dudding and Attia 2004; Howley et 
al. 2005; Robertson et al. 2006; Facco et al. 2009) The most recent of these meta-analyses 
reported a very modest overall summary odds ratio for the association between factor V 
Leiden and fetal growth restriction of 1.23 (1.04 – 1.44), however, when cohort studies were 
removed from the analysis the OR was 1.91 (1.17 - 3.12) (Facco et al. 2009). Further 
exploration of the data confirmed the effects of publication bias by demonstrating a 
significant odds ratio when early (pre-2004) studies were analysed (OR 2.04, 1.05 – 3.96, 6 
studies) whereas a non-significant odds ratio was calculated when publications from 2004 - 
2008 were included (OR 1.19, 0.02 – 2.39, 8 studies) (Facco et al. 2009).   
4. Prospective cohort studies 
While case control studies and their meta-analyses provide important data about the 
association between inherited thrombophilias and adverse pregnancy outcomes, they have 
an important limitation in that they cannot examine the “natural history” of thrombophilias 
and hence cannot ascribe causality. Prospective cohort studies are necessary to address this 
question of the potential for causality. In contrast to case control studies, prospective cohort 
studies need to recruit participants prior to the onset of any disease state and hence often 
require large numbers, making them costly and time consuming. However, undertaking 
prospective cohort studies in the setting of pregnancy has several advantages. Firstly, in 
contrast to prospective cohort studies investigating risk factors for cardiovascular disease 
and cancer, the time period is quite short and can be restricted to the duration of the 
pregnancy (ie 9 months) rather than the many years it may take for cardiovascular disease 
or cancers to develop in asymptomatic people. Secondly, pregnant women (at least in 
developed countries) are far more likely to attend for medical care at an early 
(asymptomatic) phase allowing non-biased ascertainment. Finally, many of the endpoints 
are easily measurable, routinely collected and not subject to observer or recall bias (e.g. 
birthweight, gestation at delivery, mode of delivery etc). 
A number of prospective cohort studies have now been undertaken in a variety of different 
ethnic populations. These prospective cohort studies have confirmed that inherited 
thrombophilias are indeed common with prevalence estimates for the factor V Leiden 
mutation ranging from 2.7% (Murphy et al. 2000; Dizon-Townson et al. 2005) to 10.9% 
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(Lindqvist et al. 1999). Likewise the prothrombin gene mutation is seen in 2.4% (Said et al. 
2010a) to 6.2% (Salomon et al. 2004) of women. 
Three prospective cohort studies have examined only the association between factor V 
Leiden and adverse pregnancy events, and all failed to detect a statistically significant 
difference in the rate of pregnancy complications such as pre-eclampsia, fetal growth 
restriction, placental abruption or stillbirth amongst carriers of this mutation (Lindqvist et 
al. 1999; Dizon-Townson et al. 2005; Clark et al. 2008) (although one did show an association 
between neonatal death and factor V Leiden (Clark et al. 2008)). Dudding et al examined 
both factor V Leiden and prothrombin gene mutation and concluded that neither mutation 
was associated with the development of either pre-eclampsia or fetal growth restriction 
(Dudding et al. 2008). Another study examined factor V Leiden and MTHFR 677 and found 
no significant increase in the risk of adverse pregnancy outcomes although the small sample 
size (n=584) and low prevalence of factor V Leiden (2.7%) meant that this cohort was 
underpowered to detect a significant difference (Murphy et al. 2000). Three studies 
investigated factor V Leiden, prothrombin gene mutation and also the MTHFR 677 
polymorphism (Salomon et al. 2004; Karakantza et al. 2008; Said et al. 2010a). No significant 
correlation was seen between any of these thrombophilias and adverse pregnancy outcomes 
in the study from Israel (Salomon et al. 2004). The second study, in a relatively small Greek 
cohort of 392 women, reported significant associations between factor V Leiden and MTHFR 
677 and placental abruption (Karakantza et al. 2008). Said et al also reported significant 
associations between factor V Leiden and stillbirth (OR 8.85, 1.60 – 48.92), prothrombin gene 
mutation and placental abruption (OR 12.15, 2.45 - 60.39) and a composite outcome 
comprising severe pre-eclampsia, small for gestational age (below the 5th centile), placental 
abruption and stillbirth (OR 3.58, 1.20 – 10.61) in a cohort of 1707 asymptomatic nulliparous 
women (Said et al. 2010a). In contrast, Silver et al reported no association between the 
prothrombin gene mutation and adverse pregnancy events in a  larger cohort of 4167 
women (Silver RM et al. 2010). However, most importantly, all prospective cohort studies 
have confirmed that carriers of these inherited thrombophilias can experience completely 
uncomplicated pregnancies (Rodger et al. 2010; Said et al. 2010a). 
An interesting finding from the Australian prospective cohort study (Said et al. 2010a) was 
the observation that homozygous carriers of the MTHFR 1298 polymorphism appeared to be 
at reduced risk of adverse pregnancy outcomes, and in particular fetal growth restriction. 
While the MTHFR 1298 polymorphism is not generally regarded as a thrombophilia in its 
own right and does not appear to be associated with hyperhomocysteinaemia, heterozygous 
coinheritance of the MTHFR 677 and MTHFR 1298 polymorphisms does appear to be 
associated with hyperhomocysteinaemia. Said et al have attributed their curious finding to 
the fact that the two MTHFR polymorphisms were in linkage disequilibrium suggesting that 
the protective effect observed with MTHFR 1298 homozygosity may in fact be due to the 
fact that these patients were protected from the risk of hyperhomocysteinaemia associated 
with homozygosity of MTHFR 677 (Said et al. 2010a). This possibility further supports the 
notion that absence of association in many prospective cohort studies may be because of 
failure to test for the wider range of “known” thrombophilias as well as the cumulative 
effect of common, less thrombogenic thrombophilias or unknown thrombophilias. Few 
studies have examined the MTHFR 1298 polymorphism to date to confirm or refute these 
findings. 
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5. Meta-analysis of cohort studies 
A meta-analysis of these prospective cohort studies was published in 2010 (Rodger et al. 
2010). This meta-analysis included 10 studies with 21,833 women and found no statistically 
significant increase in the risk of pre-eclampsia amongst women carrying the factor V 
Leiden mutation (OR 1.23, 0.89 - 1.70) (Rodger et al. 2010) (Figure 1). Likewise, the 
prothrombin gene mutation did not appear to confer an increase in the risk of pre-eclampsia 
with a pooled odds ratio of 1.25 (0.79 - 1.99) when 6 studies including 14,254 women were 
included (Rodger et al. 2010) (Figure 2). Similar non-significant findings were observed for 
the association between both of these thrombophilic mutations and placental abruption and 
delivery of a small for gestational age baby. In fact the only statistically significant 
association observed in this detailed meta-analysis was the significant association between 
pregnancy loss and the factor V Leiden mutation (Figure 1). It is important to note, however, 
the significant heterogeneity in the definition of pregnancy loss in the included studies, 
which comprised spontaneous miscarriage or stillbirth variably (Rodger et al. 2010). 
This meta-analysis was adequately powered to detect an absolute increase of 2% in the rate 
of pre-eclampsia in carriers of the factor V Leiden mutation (from 3.2% to 5.2%) and an 
absolute increase of 3% in carriers of the prothrombin gene mutation. However, despite the 
large numbers of patients included in this meta-analysis, the study had inadequate power to 
detect a two-fold increase in the risk of placental abruption amongst carriers of the 
prothrombin gene mutation. 
However, even with such a large meta-analysis failing to confirm significant associations 
between individual inherited thrombophilias and adverse pregnancy outcomes, several 
interpretations remain. First, of course, it is quite plausible that thrombophilia is simply not 
causative of these pregnancy complications. However, an interaction between inherited 
thrombophilia in susceptible people remains possible. Such an interaction may well result in 
augmentation of the pathological processes leading to conditions such as pre-eclampsia, or 
fetal growth restriction in susceptible people, resulting in earlier onset and more severe 
disease in these people. Such an explanation would be supported by the apparent 
contradiction between case-control studies and prospective cohort studies. An alternative 
possibility is that additional, as yet unidentified thrombophilias may result in a cumulative 
effect that determines the disease phenotype once a critical threshold is reached. This 
hypothesis is supported by observations from case-control studies that demonstrate the 
presence of multiple inherited thrombophilias being more commonly found in women with 
more severe complications than in apparently asymptomatic women. This issue would be 
relevant in the many case-control and cohort studies that only examine a single 
thrombophilic polymorphism rather than a panel of common polymorphisms. 
A key feature of the association between inherited thrombophilias and pregnancy 
complications that has been particularly borne out by the prospective cohort studies is the 
lack of specificity between individual thrombophilias and particular complications. For 
example both the factor V Leiden mutation and the prothrombin gene mutation have been 
variably associated with normal pregnancy outcomes, fetal growth restriction, pre-
eclampsia, placental abruption, stillbirth and recurrent miscarriage. Conversely, the  
phenotype of these disorders appears identical regardless of which thrombophilic mutation 
(if any) is carried.  In addition, in a patient who carries one of these mutations, it is unclear 
what additional modifying factors will determine the precise outcome. 
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Fig. 1. Meta-analysis of pregnancy complications in women who are heterozygous or 
homozygous for factor V Leiden. (Rodger et al. 2010) 
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Fig. 2. Meta-analysis of pregnancy complications in women who are heterozygous or 
homozygous for prothrombin gene mutation. (Rodger et al. 2010) 
Given the range of potential thrombophilias that could be investigated in an individual, the 
lack of specificity with disease states and the possibility of “unknown” or unidentified 
thrombophilias contributing to the phenotype, the appropriateness of investigating women 
for inherited thrombophilias to predict the risk for future pregnancy complications must be 
questioned. Thrombophilia testing is expensive. Furthermore there are conflicting data 
concerning the subsequent risks of recurrent adverse pregnancy outcomes such as pre-
eclampsia (van Rijn et al. 2006; Facchinetti et al. 2009) in women who carry an inherited 
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thrombophilia compared to those who don’t, so the benefits of detecting these markers 
remain uncertain. This in turn makes the rationale of treating subsequent pregnancies with 
prophylactic heparins questionable. An alternative approach is to treat the disease 
phenotype rather than simply the test result!  
6. Placental thrombotic lesions and inherited thrombophilias 
Placental vasculopathy is a histopathological diagnosis which is increasingly being 
recognised in association with a variety of clinical pathologies including pre-eclampsia, fetal 
growth restriction, placental abruption and stillbirth. In addition, a number of reports 
regarding the association between these pathologic features and cerebral palsy have been 
published (Arias et al. 1998; Kraus and Acheen 1999). Redline and Pappin were amongst the 
first to report these specific placental lesions and their association with adverse neonatal 
outcomes. In addition they defined the pathologic criteria for diagnosis of this condition 
(Redline and Pappin 1995). While Kraus and Acheen (Kraus and Acheen 1999) have 
demonstrated that these lesions precede fetal death in cases of stillbirth, the precise 
pathophysiological mechanism resulting in the vascular thrombosis and fibrosis is 
unknown. Nevertheless it has been considered plausible that procoagulant states such as 
thrombophilias may contribute.  
Many and colleagues (Many et al. 2001) investigated the contribution of maternal 
thrombophilias to the pathologic placental features in women with severe pregnancy 
complications and concluded that placental abnormalities such as infarcts and fibrinoid 
necrosis were more common in the placentae of women with pregnancy complications and 
thrombophilia compared to those with the same complications without thrombophilia. Of 
note, however, the women with thrombophilia and complications delivered at an earlier 
gestation and had lower birthweight babies compared to their non-thrombophilic 
counterparts. Thus whether these differences truly represent a difference in thrombophilia 
state or simply a difference in phenotypic state must be questioned. Likewise, Gogia and 
Machin (Gogia and Machin 2008) investigated the association between the specific placental 
lesions of maternal floor infarction (n=40), massive perivillous fibrin deposition (n=87) and 
fetal thrombotic vasculopathy (n=7) and identified a range of maternal thrombophilic markers  
in 40%, 23% and 71% respectively of  the women with these placental histopathological 
diagnoses. The prevalence of thrombophilias in these women was significantly higher than the 
background prevalence of these same thrombophilias in the published literature.  
In contrast, Mousa and Alfirevic (Mousa and Alfirevic 2000) were unable to detect a 
difference in placental histopathology amongst 43 thrombophilic women with adverse 
pregnancy outcome, who were compared to 36 non-thrombophilic women with the same 
adverse pregnancy outcomes. The validity of this study has however been questioned given 
that histopathological examination was performed as part of routine clinical investigation 
and management rather than being performed in a rigorous standardised manner, thereby 
leaving the final results and therefore conclusions potentially subject to bias (Khong et al. 
2001). Likewise, Kahn et al examined the association between inherited thrombophilias and 
placental lesions reflecting underperfusion in a nested case-control study, and concluded 
that although the placental lesions were more common in cases of pre-eclampsia compared 
to controls, there was no correlation with maternal thrombophilia (Kahn et al. 2009).     
In one of the largest studies to date, Rogers and colleagues prospectively collected and 
examined 105 placentae from women carrying the factor V Leiden mutation and 225 
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controls matched for maternal age, ethnicity and hospital (Rogers et al. 2010). They reported 
an increase in the frequency of syncytial knots (adjusted OR 3.6, 1.5 - 8.7 after controlling for 
hypertension, pre-eclampsia, small for gestational age fetus and preterm delivery before 35 
weeks) and hypervascular villi (adjusted OR 3.4, 1.2 - 9.4 after controlling for mode of 
delivery) in placentae from women who were heterozygous for the factor V Leiden 
mutation. In contrast to the previous studies, this study did not demonstrate an increase in 
the frequency of placental infarcts, small for gestational age placentae or fetal thrombotic 
vasculopathy. An important limitation of this study, however, was that although testing for 
the prothrombin gene mutation and MTFR 677 polymorphism were performed, the 
numbers were too small to assess whether these polymorphisms also contributed to the 
placental pathological findings. Furthermore, subjects did not undergo testing for other 
known thrombophilias, raising the possibility that the pathologic lesions observed in control 
subjects may also be attributable to other thrombophilias     
7. Fetal thrombophilias 
It is of course plausible that it is the fetal thrombophilic status that is the strongest predictor 
of adverse pregnancy outcomes, fetal thrombotic vasculopathy and associated placental 
lesions. Given that inherited thrombophilias are generally inherited in an autosomal 
dominant fashion, the fetus would only have a 50% chance of inheriting maternal 
thrombophilias and this may explain why not all pregnancies appear to be affected. 
Placental tissue carries (in most cases) the same genotype as the fetus. A thrombophilic 
tendency in the placenta could therefore be conferred via the inheritance of paternally 
derived thrombophilias. The possibility that it is the fetal genotype, rather than the 
maternal, contributing to the development of fetal growth restriction was first suggested by 
a case report describing dizygotic twins with severe growth discordance. The patient had a 
past history of fetal growth restriction, placental abruption and pulmonary embolism and 
was found to be a compound heterozygote for the two MTHFR polymorphisms (677 and 
1298) (Khong and Hague 2001). The twins demonstrated differential inheritance of the 
parental MTHFR genes, with the placenta of the smaller twin also demonstrating features of 
thrombotic vasculopathy. While dizygotic twins provide a unique opportunity for assessing 
the possible impact of fetal inheritance of thrombophilias, it is important to remember that a 
number of twins will have significant growth discordance which will partly relate to 
unequal utero-placental share, aside from any difference in thrombophilia state. 
Ariel and colleagues investigated the association between fetal thrombophilia status and 
placental lesions but were unable to identify a statistically significant difference in the 
prevalence of placental thrombotic lesions between neonatal or maternal carriers of 
thrombophilia (Ariel et al. 2004). Rogers also investigated the potential contribution of fetal 
thrombophilias to the histopathologic appearance and found an increase in the frequency of 
avascular villi in placentae from 50 infants who carried the factor V Leiden mutation 
(Rogers et al. 2010). Forty of these infants inherited the mutation from the mother while 10 
inherited it from the father. Of note, fetal inheritance of factor V Leiden was not associated 
with fetal thrombotic vasculopathy, placental infarction or small for gestational age 
placentae (Rogers et al. 2010). 
An Australian study (Gibson et al. 2006) reported a significant association between fetal 
inheritance of the prothrombin gene mutation (heterozygous or homozygous) and fetal 
growth restriction (birthweight less than the 10th centile) in babies born prior to 28 weeks 
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(odds ratio 5.71, 95% CI 1.49 - 21.93). Subgroup analysis for those babies with a birthweight 
less than the fifth centile also confirmed this finding. 
Livingston also undertook a case control study investigating the relationship between 
maternal and fetal inherited thrombophilias and pre-eclampsia (Livingston et al. 2001). 
Although the large population of African American patients included in the study (and thus 
low prevalence of inherited thrombophilias) may have biased this study, Livingston 
concluded that neither maternal nor fetal inherited thrombophilias were associated with 
pre-eclampsia 
Given these various reports, the association between inherited thrombophilias and placental 
thrombotic lesions appears to be weak at best and there are numerous confounding issues 
that must be considered such as the presence of additional maternal medical disorders, 
pregnancy complications and the complexities of the maternal-fetal genetic and immune 
interactions. Therefore recommendations for routine testing of entire families on the basis of 
placental findings (as suggested by Gogia (Gogia and Machin 2008)) are thus premature and 
raise concerns about the ethical implications of testing asymptomatic carriers.  
8. The role of anticoagulants in preventing pregnancy complications in 
thrombophilic women 
Despite the contradictory findings of studies investigating the association between inherited 
thrombophilias and adverse pregnancy outcomes, anticoagulant treatment for pregnant 
women who carry inherited thrombophilias has been embraced by many on the basis of 
small, non-randomised studies (Riyazi et al. 1998; Kupferminc et al. 2001; Ogueh et al. 2001; 
Grandone et al. 2002) and several larger randomised controlled trials with methodological 
limitations (Gris et al. 2004; Brenner et al. 2005). The rationale for anticoagulant treatment 
relies on the effect of anticoagulants in treating venous thromboembolism. A number of 
large scale randomised controlled trials investigating the role of low molecular weight 
heparins in preventing miscarriage in women who experience recurrent miscarriages have 
recently reported negative results (Clark et al. 2010; Kaandorp et al. 2010; Visser et al. 2011).  
Meanwhile, the FRUIT study, (FRagmin®) in pregnant women with a history of 
Uteroplacental Insufficiency and Thrombophilia: a randomised trial (FRUIT) 
ISRCTN87325378), has recently been completed and demonstrated a small but statistically 
significant reduction in the risk of recurrent early onset pre-eclampsia or small for 
gestational age infant in thrombophilic women with a previous history of early onset pre-
eclampsia or fetal growth restriction (de Vries et al. 2011). This multicentre trial randomised 
139 thrombophilic women with prior adverse pregnancy outcomes (pre-eclampsia or small 
for gestational age infant with delivery prior to 34 weeks) to receive low molecular weight 
heparin (Fragmin®) (dosage adjusted for maternal weight) and aspirin 80mg or aspirin 80mg 
alone. Overall there was a statistically significant reduction in the primary outcome of pre-
eclampsia or small for gestational age infant requiring delivery prior to 34 weeks, p=0.012 
without any significant increase in the risk of adverse effects (de Vries et al. 2011). 
While these data are encouraging, it must be emphasised that thrombophilic women with a 
history of prior adverse pregnancy outcomes such as those included in this study, represent 
only a very small proportion of the overall subgroup of women at risk of these serious 
pregnancy events and that many of these women do in fact achieve successful pregnancy 
outcomes with the far less expensive, less invasive and simple treatment regime of low dose 
aspirin which has been shown in an individual patient data meta-analysis to reduce the risk 
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of recurrent pre-eclampsia and fetal growth restriction by up to 10% (Askie et al. 2007). The 
findings of the FRUIT study need to be confirmed in other, larger populations before this 
treatment should be recommended and certainly before this practice is extrapolated to other 
subgroups of thrombophilic patients (eg those with a prior stillbirth). The TIPPS study 
(Thrombophilia in Pregnancy Prophylaxis Study, ISRCTN87441504) is an ongoing 
multicentred randomised trial that will provide further data in this regard and may help to 
resolve some of these dilemmas. 
However, as stated previously, the vast majority of women with these pregnancy 
complications do not have an identifiable thrombophilic marker, yet the mechanisms 
contributing to thrombotic lesions within the placenta remain uncertain. Moreover, the 
potential for anticoagulant prophylaxis to be of benefit in these women, as well as in women 
with identified thrombophilias, is limited by our lack of knowledge and understanding 
about the mechanisms involved in regulation of haemostasis in the placenta and potential 
actions of heparins in this organ. 
9. Regulation of haemostasis in the placenta  
Thrombotic lesions are observed commonly in placentae from women who experience 
pregnancy complications (Salafia et al. 1995a; Salafia et al. 1995b). Mechanisms regulating 
haemostasis within the placenta remain poorly understood (Sugimura et al. 2001; Lockwood 
et al. 2011; Said 2011). However, there is clear evidence of enhanced activation of the 
coagulation and fibrinolytic systems within both the uteroplacental and systemic 
circulations of women with pre-eclampsia compared to those with uncomplicated 
pregnancies (Higgins et al. 1998). As described previously, analysis of the published case-
control studies reporting associations between inherited thrombophilias and adverse 
pregnancy events suggest that these associations are strongest with the more severe and 
earlier onset complications rather than with milder, later-onset conditions suggesting in fact 
that thrombophilias may exacerbate an underlying tendency toward the condition rather 
than causing it per se.   
In vivo, coagulation and inflammatory pathways are intimately related (reviwed by Esmon 
(Esmon 2005)). The coagulation cascade is triggered with the exposure of tissue factor at the 
site of injury. Tissue factor is abundantly expressed in the decidua and first trimester 
trophoblast cells. Thus, invasion of the decidua during the first trimester by extravillous 
trophoblast cells is accompanied by profound local thrombin generation (which ultimately 
activates platelets and allows conversion of fibrinogen to fibrin) which protects against local 
haemorrhage. At the same time inflammatory processes are triggered which result in the 
production of inflammatory cytokines such as tumour necrosis factor-α (TNF-α), endotoxin 
and CD40 ligand, all of which induce tissue factor expression on the surface of white blood 
cells (especially monocytes), thereby augmenting the coagulation cascade (Esmon 2005). 
Furthermore, inflammatory mediators such as interleukin 6 (IL 6) increase both platelet 
numbers and platelet activation (Esmon 2005). These factors all contribute to the systemic 
procoagulant state observed in pregnancy. However, this system must be tightly regulated 
locally to prevent uncontrolled thrombosis. Thrombomodulin is also widely expressed on 
trophoblast cells (Isermann et al. 2003; Weiler 2004). The binding of thrombin to 
thrombomodulin results in activation of protein C. There is a modest but progressive 
increase in systemic protein C levels during the first half of pregnancy which may help to 
regulate haemostasis (Said et al. 2010b). Furthermore, it is now recognized that activated 
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protein C plays an important role in the regulation of the inflammatory system through 
suppression of Tumour Necrosis Factor-α (TNFα) and inflammatory cytokine expression 
(Esmon 2001; Toltl LJ et al. 2008), which is mediated by protein C inhibition of Nuclear 
Factor-ĸB (NF-ĸB) translocation (Murakami et al. 1997).  
Proteoglycans are macromolecules located within vessel walls and these are also abundantly 
expressed in human placentae. Being membrane bound, they act locally with exceptionally 
low levels detectable in maternal plasma (Giri and Tollefsen 2006). Proteoglycans were 
previously regarded as simply structural molecules responsible only for maintaining the 
“shape” and structural integrity of organs. It is now known that these molecules have 
important biological functions including anticoagulant properties, interactions with growth 
factors (particularly angiogenic growth factors such as VEGF and PlGF) (Santra et al. 2008)  
and anti-inflammatory properties, making them a potentially important group of candidate 
molecules in regulating placental haemostasis and potentially playing a role in the 
pathogenesis of pregnancy disorders (Schaefer and Iozzo 2008; Whitelock et al. 2008; Said 
2011). Proteoglycans comprise a core protein to which sulphated glycosaminoglycans (GAG) 
chains are covalently linked. There are four types of GAG chains located in the blood vessel 
wall: Chondroitin Sulphate (CS), Dermatan Sulphate (DS), Heparan Sulphate (HS) and 
Hyaluronan (HA). (Iozzo 2005) Placentae contain two major types of proteoglycans; those 
containing heparan sulphate (syndecans, perlecan) (Jokimaa et al. 1998) and those 
containing dermatan sulphate (decorin and biglycan) (Murthi et al. 2010; Swan et al. 2010). 
HS chains bind Antithrombin (AT) – a potent inhibitor of thrombin - through a 
pentasaccharide sequence, and DS chains bind Heparin Cofactor II (HCII) through a highly 
charged sequence (Chen and Liu 2005).  GAG bound AT and HCII undergo a 
conformational change, which in turn facilitates the inhibition of thrombin (Brinkmeyer et 
al. 2004). The cellular localization of proteoglycans to endothelium and cells in contact with 
circulating blood, suggest an important role for these molecules in localized anticoagulation.  
Previous studies have demonstrated significant reductions in mRNA expression of  decorin 
(Swan et al. 2010) and biglycan (Murthi et al. 2010) in placentae from pregnancies affected 
by fetal growth restriction (FGR) compared to gestation matched control placentae using 
semi-quantitative RT-PCR (relative to the house keeping gene GAPDH). Warda et al also 
demonstrated a significant reduction in the expression of GAG synthesizing enzymes in 
preeclamptic placentae compared to controls (Warda et al. 2008). This reduction translated 
to a significant alteration in GAG structure raising the possibility that the altered GAG 
structure may have functional corollaries which may contribute to the development of pre-
eclampsia. 
Proteoglycans also play important roles in angiogenic pathways by acting as receptors for 
growth factors. Disordered angiogenesis has been implicated as a key pathogenic 
mechanism contributing to pregnancy disorders such as pre-eclampsia and fetal growth 
restriction (comprehensively reviewed by Young et al (Young et al. 2010)) Vascular 
endothelial growth factor (VEGF) plays an important role in stabilizing the endothelium in 
mature blood vessels (Maharaj et al. 2008). Placental growth factor (PlGF) has structural 
homology to VEGF and is thought to amplify VEGF signalling (Autiero et al. 2003). VEGF 
and PlGF are highly expressed by invasive cytotrophoblasts involved in spiral artery 
remodeling. However, in preeclamptic pregnancies, VEGF and PlGF levels are substantially 
lower than non-preeclamptic controls (Young et al. 2010). The soluble form of the VEGF 
receptor fms-like tyrosine kinase (sFlt1), an antagonist of VEGF, is significantly elevated in 
pre-eclamptic pregnancies (Young et al. 2010). Similarly transforming growth factor ß (TGF-
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ß) and endoglin (Eng) levels are higher in pre-eclamptic pregnancies compared to controls 
although whether this is a primary pathologic mechanism or a compensatory mechanism 
resulting from ongoing placental ischemia remains uncertain. sFlt1 and sEng, the soluble 
forms of FLt1 and Eng respectively are released into maternal plasma during pre-eclampsia 
and exert their antiangiogenic effects on maternal endothelium leading to a state of 
generalized endothelial dysfunction (Young et al. 2010). 
The interaction between haemostatic pathways and angiogenic pathways is further 
illustrated by the finding that thrombin significantly augments first trimester (but not term) 
decidual expression of sFlt-1 (Lockwood et al. 2007). Thus, dysregulation of the complex 
haemostatic pathway by any one of a range of possible mechanisms during the first 
trimester, has the potential to lead to a cascade of events which may collectively lead to the 
pathophysiological processes observed in pregnancies complicated by adverse events such 
as pre-eclampsia. 
The combination of endothelial dysfunction, altered blood flow dynamics secondary to 
abnormal vasculature and the hypercoagulable state of pregnancy provides a plausible 
background for the development of intravascular microthrombi, which in turn can result in 
a positive feedback loop leading to greater tissue ischaemia, ongoing oxidative stress and 
endothelial dysfunction thus perpetuating intravascular thrombosis and ultimately leading 
to the characteristic placental lesions we observe in pregnancy disorders such as pre-
eclampsia, placental abruption, fetal growth restriction and stillbirth. It is plausible that 
dysregulation of these processes are far more important in leading to the pathogenesis of 
adverse pregnancy events than inherited thrombophilias. 
10. The role of anticoagulants in “non-thrombophilic” patients  
Recent randomised controlled trials (RCTs) investigating the role of low molecular weight 
heparins (LMWH) in preventing adverse pregnancy outcomes in non-thrombophilic women 
have suggested beneficial effects (Rey et al. 2009; Gris JC et al. 2010) raising the possibility 
that it is a primary placental haemostatic defect contributing to the pathogenesis of these 
conditions rather than a maternal thrombophilia. Data from these RCT’s are supported by 
non-randomised observational studies in which non-thrombophilic women with previous 
obstetric complications and associated evidence of placental vasculopathy had improved 
obstetric outcomes when treated with LMWH in subsequent pregnancies (Kupferminc et al. 
2011). These studies are indeed promising and suggest the more rational use of 
anticoagulants using an appropriate “phenotype” driven approach (ie on the basis of 
disease severity and corroborating placental histopathological findings) rather than just a 
genotype (presence of thrombophilia) driven approach. However a note of caution must be 
applied. Firstly, the precise mechanism by which low molecular weight heparins achieve 
beneficial obstetric outcomes remains obscure. Heparin is a synthetic glycosaminoglycan 
with augmented anticoagulant activity. Whether heparins produce their therapeutic effects 
in these pregnancy situations via their anticoagulant action or whether through non-
anticoagulant (inflammatory or angiogenic mechanisms as discussed previously) has not yet 
been determined. Understanding these mechanisms may provide the basis for developing 
more efficacious and safe agents. Secondly, none of the randomised trials published to date 
have been adequately powered to assess uncommon but serious potential consequences of 
treatment. Although low molecular weight heparins are generally regarded as “safe”(Greer 
and Nelson-Piercy 2005), they have important implications for labour epidural use 
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(Horlocker et al. 2010) and risks of wound bleeding and haematoma (van Wijk et al. 2002) 
following operative delivery. These comparatively minor risks are particularly important 
given the third issue which is the fact that prophylaxis is given to prevent recurrence of 
placental mediated complications, but untreated women appear to only have a risk of at 
most 25-30% (van Rijn et al. 2006; Rey et al. 2009) for these recurrent complications, therefore 
potentially 70% or more of these women are exposed to this treatment without necessarily 
needing it. Strategies to better predict who will benefit from such therapy are urgently 
needed but what does appear clear is that prediction on the basis of presence or absence of a 
known inherited thrombophilia is not a useful or worthwhile strategy. 
Kingdom et al attempted to better stratify women by incorporating a range of tests of 
placental function prior to including women in a pilot randomised trial of unfractionated 
heparin in women at risk of placental mediated obstetric complications (Kingdom et al. 
2011). However, even despite this rigorous screening process, only 12% of women 
developed pre-eclampsia and 25% of the infants had intrauterine growth restriction in the 
standard care arm (Kingdom et al. 2011). The high prevalence of placental pathology, 
however was confirmed with only 5/31 normal placentae (4 in the unfractionated heparin 
group and one in the standard care group) identified. Although this study was 
underpowered to determine whether unfractionated heparin is beneficial in this setting, it 
does highlight the need for improved identification and stratification of patients who may 
benefit from this somewhat invasive therapy. Furthermore, the choice of unfractionated 
heparin in this study contrasts with that of previous studies which predominantly use low 
molecular weight heparins.  
11. Conclusions 
Inherited thrombophilias are common amongst women of reproductive age. However, we 
can be reassured by the prospective cohort studies and the meta-analysis of such studies 
that the majority of asymptomatic women who carry these inherited thrombophilias will not 
experience adverse pregnancy outcomes. What is less certain is the potential adjuvant role 
that thrombophilias may play in women at increased risk for other reasons of these 
complications or in women who are developing these complications. Also of concern is the 
large number of women who experience adverse pregnancy complications who do not carry 
a recognisable inherited or acquired thrombophilia. Understanding the precise mechanisms 
regulating coagulation within the placenta will be an important priority in order to establish 
the most efficacious therapeutic options for this majority of women experiencing these 
complications. Only then should the effects of and differences between the variety of 
available anticoagulants be investigated to ensure that these therapeutic agents are used in 
the most effective and rational manner to either treat or prevent serious adverse pregnancy 
events.   
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